Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

75.0%

3 terminated/withdrawn out of 4 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1

2(50.0%)

Phase 3

1(25.0%)

Early Phase 1

1(25.0%)

4Total

Phase 1(2)

Phase 3(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT01526408Phase 3Terminated

Famvir for Treatment of Hearing in Unilateral Meniere's Disease

Role: lead

NCT00863122Early Phase 1Completed

Concentration and Activity of Lapatinib in Vestibular Schwannomas

Role: collaborator

NCT01850225Phase 1Withdrawn

Feasibility Study of Auditory Brainstem Implant in Young Children

Role: lead

NCT01526174Phase 1Terminated

Intratympanic Injection for Autoimmune Inner Ear Disease

Role: lead

All 4 trials loaded